Hyperthermic Intraperitoneal Chemotherapy for Advanced Gastric Cancer With Peritoneal Metastatis

Summary

The incidence rate of gastric cancer is high in Southeast Asia, so is the mortality rate.Due to the lack of specific performance, about 5%-20% of patients have found peritoneal metastases at the time of first diagnosis.At present, clinical studies on HIPEC in the treatment of patients with advanced gastric cancer peritoneal metastasis are almost related to abdominal perfusion after laparoscopic gastrectomy.Herein, we conduct a single-centre randomized controlled trial to explore the safety and feasibility of laparoscopic exploration combined with HIPEC in the treatment of advanced gastric cancer with peritoneal metastasis.

Timeline

Start

2017-06-01

Primary completion

2017-08-24

Completion

2020-08-24

Outcome

Missed primary endpoint

paper Compared to the HIPEC group, the SOX group had a significantly higher median PFS PMID 40115934 ↗

paper This trial failed to show the superiority of HIPEC with SOX over SOX alone. PMID 40115934 ↗

Publications

• Luo L, Zhang Z, Zeng H, Xu Y, Peng Y, Huang H, Lin Z, Xiong W, Wang W. Hyperthermic intraperitoneal chemotherapy plus SOX chemotherapy versus SOX chemotherapy alone in patients with gastric cancer and peritoneal metastasis: a phase II randomized clinical trial. J Gastrointest Oncol. 2025 Feb 28;16(1):17-26. doi: 10.21037/jgo-24-807. Epub 2025 Jan 9.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Paclitaxel	Small molecule	50 mg/m2	Other
Comparator	Oxaliplatin	Small molecule	130 mg/m2	Intravenous
Comparator	Tiggio	Unknown	40 mg	Oral
Comparator	Tiggio	Unknown	50 mg	Oral
Comparator	Tiggio	Unknown	60 mg	Oral

Indications